Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, et al.
Trends in Immunology (2021) Vol. 42, Iss. 3, pp. 209-227
Open Access | Times Cited: 159

Showing 26-50 of 159 citing articles:

Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
Jessica Konen, Haoyi Wu, Don L. Gibbons
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 520-536
Closed Access | Times Cited: 9
YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Zhehui Zhu, Rui Ding, Wei Yu, et al.
Cell Death and Differentiation (2025)
Open Access | Times Cited: 1
Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer
Y. Tu, Asma Ayari, Roddy S. O’Connor
Antibodies (2021) Vol. 10, Iss. 3, pp. 25-25
Open Access | Times Cited: 43
Immune cellular components and signaling pathways in the tumor microenvironment
Sasitorn Yenyuwadee, Konstantinos Aliazis, Qi Wang, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 187-201
Open Access | Times Cited: 33
Specialized functions and sexual dimorphism explain the functional diversity of the myeloid populations during glioma progression
Natalia Ochocka, Paweł Segit, Kamil Wojnicki, et al.
Cell Reports (2023) Vol. 42, Iss. 1, pp. 111971-111971
Open Access | Times Cited: 19
PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion
Jennifer L. Hope, Dennis C. Otero, Eun‐Ah Bae, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112436-112436
Open Access | Times Cited: 19
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110417-110417
Open Access | Times Cited: 18
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Zhaoyun Liu, Xintong Xu, Hui Liu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Immunometabolic reprogramming, another cancer hallmark
Vijay Kumar, John H. Stewart
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
The Human Ganglioside Interactome in Live Cells Revealed Using Clickable Photoaffinity Ganglioside Probes
Gao‐Lan Zhang, Mitchell J. Porter, Abduselam K. Awol, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 26, pp. 17801-17816
Closed Access | Times Cited: 8
Expression and function of VISTA on myeloid cells
Siyu Li, Geng Wang, Yan Ren, et al.
Biochemical Pharmacology (2024) Vol. 222, pp. 116100-116100
Closed Access | Times Cited: 7
Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside
Farid Ghorbaninezhad, Zahra Asadzadeh, Javad Masoumi, et al.
Life Sciences (2022) Vol. 297, pp. 120466-120466
Closed Access | Times Cited: 26
VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated
Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi
Life Sciences (2022) Vol. 310, pp. 121083-121083
Closed Access | Times Cited: 26
Modelling the tumor immune microenvironment for precision immunotherapy
Nathan J. Mackenzie, Clarissa Nicholls, Abby R. Templeton, et al.
Clinical & Translational Immunology (2022) Vol. 11, Iss. 6
Open Access | Times Cited: 24
Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial
Chengxiang Guo, Junlei Zhang, Xin Huang, et al.
Hepatology Communications (2023) Vol. 7, Iss. 3, pp. e0054-e0054
Open Access | Times Cited: 16
Circulating and Tumor-Associated Neutrophils in the Era of Immune Checkpoint Inhibitors: Dynamics, Phenotypes, Metabolism, and Functions
Lara Gibellini, Rebecca Borella, Elena Santacroce, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3327-3327
Open Access | Times Cited: 16
Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma
Jian-wen Di, Yixin Wang, Ruixue Ma, et al.
Cell Biology and Toxicology (2024) Vol. 40, Iss. 1
Open Access | Times Cited: 6
VISTA: a novel checkpoint for cancer immunotherapy
Yu Gao, Yanting He, Yuanyuan Tang, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 7, pp. 104045-104045
Closed Access | Times Cited: 6
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
Yusheng Lin, Ghizlane Choukrani, Lena Dübbel, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors
Jiawei Fan, Jianshu Zhu, He Zhu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 198, pp. 104362-104362
Open Access | Times Cited: 5
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
Tatiana Vilela, Sofia Valente, Jorge Correia, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189144-189144
Open Access | Times Cited: 5
Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy
Eunji Im, Deok Yong Sim, Hyo-Jung Lee, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 1066-1075
Open Access | Times Cited: 31
Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha
Na Li, Shanru Yang, Yan Ren, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115492-115492
Closed Access | Times Cited: 12
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
Xiaoshuang Niu, Menghan Wu, Guodong Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 11, pp. 4511-4522
Open Access | Times Cited: 11
Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Randolph J. Noelle, J. Louise Lines, Lionel D. Lewis, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11

Scroll to top